Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO... by Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan M., Jabbour, Elias, Wang, Tao, Liang White, Jane, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.

Get full text

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial by Wu, Yi-Long, Cheng, Ying, Zhou, Xiangdong, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Niho, Seiji, Tsuji, Fumito, Linke, Rolf, Rosell, Rafael, Corral, Jesus, Migliorino, Maria Rita, Pluzanski, Adam, Sbar, Eric I, Wang, Tao, White, Jane Liang, Nadanaciva, Sashi, Sandin, Rickard, Mok, Tony S

Get full text

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin by Jabbour, Elias, Advani, Anjali S., Stelljes, Matthias, Stock, Wendy, Liedtke, Michaela, Gökbuget, Nicola, Martinelli, Giovanni, O'Brien, Susan, White, Jane Liang, Wang, Tao, Luisa Paccagnella, M., Sleight, Barbara, Vandendries, Erik, DeAngelo, Daniel J., Kantarjian, Hagop M.

Get full text

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Pati... by Sharma, Sheena, Wang, Diane, Lon, Hoi-Kei, Soltantabar, Pooneh, Viqueira, Andrea, Czibere, Akos, Hickman, Anne, White, Jane Liang, Elmeliegy, Mohamed

Get full text

P-274 Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies by Ishida, Tadao, Yokoyama, Hisayuki, Suzuki, Kenshi, Ito, Satoshi, Nagai, Yuya, Handa, Hiroshi, Ito, Shigeki, Kamei, Yoichi, Nakamura, Masatoshi, Viqueira, Andrea, White, Jane Liang, Take, Kazumi, Moribe, Toyoki, Iida, Shinsuke

Get full text

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study by Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Goekbuget, Nicola, O'Brien, Susan M., Jabbour, Elias J., Wang, Tao, White, Jane Liang, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.

Get full text

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status by Advani, Anjali S., Jabbour, Elias J., Stelljes, Matthias, Stock, Wendy, Liedtke, Michaela, Goekbuget, Nicola, O'Brien, Susan M., White, Jane Liang, Wang, Tao, Laird, A. Douglas, Vandendries, Erik, Kantarjian, Hagop M.

Get full text

Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media by Prowse, Andrew B.J, Doran, Michael R, Cooper-White, Justin J, Chong, Fenny, Munro, Trent P, Fitzpatrick, Jane, Chung, Tung-Liang, Haylock, David N, Gray, Peter P, Wolvetang, Ernst J

Get full text

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer by Liang, Jun, Zbieg, Jason R., Blake, Robert A., Chang, Jae H., Daly, Stephen, DiPasquale, Antonio G., Friedman, Lori S., Gelzleichter, Thomas, Gill, Matthew, Giltnane, Jennifer M., Goodacre, Simon, Guan, Jane, Hartman, Steven J., Ingalla, Ellen Rei, Kategaya, Lorn, Kiefer, James R., Kleinheinz, Tracy, Labadie, Sharada S., Lai, Tommy, Li, Jun, Liao, Jiangpeng, Liu, Zhiguo, Mody, Vidhi, McLean, Neville, Metcalfe, Ciara, Nannini, Michelle A., Oeh, Jason, O’Rourke, Martin G., Ortwine, Daniel F., Ran, Yingqing, Ray, Nicholas C., Roussel, Fabien, Sambrone, Amy, Sampath, Deepak, Schutt, Leah K., Vinogradova, Maia, Wai, John, Wang, Tao, Wertz, Ingrid E., White, Jonathan R., Yeap, Siew Kuen, Young, Amy, Zhang, Birong, Zheng, Xiaoping, Zhou, Wei, Zhong, Yu, Wang, Xiaojing

Get full text

Vaccine Hyporesponse Induced by Individual Antibiotic Treatment in Mice and Non-Human Primates Is Diminished upon Recovery of the Gut Microbiome by Swaminathan, Gokul, Citron, Michael, Xiao, Jianying, Norton, James E., Reens, Abigail L., Topçuoğlu, Begüm D., Maritz, Julia M., Lee, Keun-Joong, Freed, Daniel C., Weber, Teresa M., White, Cory H., Kadam, Mahika, Spofford, Erin, Bryant-Hall, Erin, Salituro, Gino, Kommineni, Sushma, Liang, Xue, Danilchanka, Olga, Fontenot, Jane A., Woelk, Christopher H., Gutierrez, Dario A., Hazuda, Daria J., Hannigan, Geoffrey D.

Get full text

Regulatory news: Nulibry (fosdenopterin) approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency type A: FDA approval summary by Farrell, Sheila, Karp, Jacqueline, Hager, Rebecca, Wang, Yan, Adeniyi, Oluseyi, Wang, Jie, Li, Liang, Ma, Lian, Peretz, Jackye, Summan, Mukesh, Kong, Nicolas, White, Michael, Pacanowski, Michael, Price, Dionne, Filie, Jane, Donohue, Kathleen, Joffe, Hylton

Get full text